

SUPPLEMENT 1

Nikitina A.S., Babenko V.V., Babalyan K.A., Vasiliev A.O., Govorov A.V., Prilepskaya E.A., Danilenko S.A., Selezneva O.V., Sharova E.I., Primary candidate rna biomarker screening by RNA-seq for prostate cancer diagnostics, Biomeditsinskaya khimiya, 2015, vol: 61(6), 781-784. DOI: 10.18097/PBMC20156106781

RNA biomarkers associated with prostate cancer according to the literature and their representation in analyzed samples.

Potential RNA biomarker for prostate cancer	Samples				Source
	P1	P2	U3	U4	
MALAT1	+	+	+	+	1
NCOR1	+	+	+	+	2
NEAT1	+	+	+	+	3
ATM	+	+	-	+	4
NCOA1	+	+	-	+	5
NCOA2	+	-	+	+	6
NCOR2	+	+	-	+	7
PRKDC	+	-	+	+	8
PTEN	+	+	-	+	9
IGF1R	-	-	+	+	10
MAGI2	-	+	-	+	11
MED12	-	-	+	+	12
PHLPP1	-	+	-	+	13
PRUNE2	-	-	+	+	14
SPOP	-	-	+	+	15
APC	+	-	-	+	16
CHD1	+	-	-	+	17
GREB1	+	-	-	+	18
PIK3CA	+	-	-	+	19
RB1	+	-	-	+	20
ACPP	-	-	-	+	21

AKT1	-	-	-	+	22
AMACR	-	-	-	+	23
AR	-	-	-	+	24
BMI1	-	-	-	+	25
BRAF	-	-	-	+	26
CADM2	-	+	-	-	27
CTNNB1	-	-	-	+	28
CYP17A1	-	-	-	+	29
EGFR	-	-	-	+	30
ERCC4	-	-	+	-	31
ERCC5	-	-	-	+	31
EZH2	-	-	-	+	25
FOXA1	-	-	-	+	32
GSTP1	-	-	-	+	33
KLK3	-	-	-	+	34
MYC	-	-	-	+	35
NCOA3	-	-	-	+	36
NDRG1	-	-	-	+	37
NKX3-1	-	-	-	+	38
PCAT1	-	-	-	+	3
PMEPA1	-	-	-	+	39
RHOB	-	-	-	+	40
SRC	-	-	-	+	41
TMPRSS2	-	-	-	+	42
TNK2	-	-	-	+	43
TP53	-	-	-	+	44
TP53INP2	-	-	-	+	45
AURKA	-	-	-	-	46

BMP7	-	-	-	-	47
CDK1	-	-	-	-	48
CDK2	-	-	-	-	49
ERCC2	-	-	-	-	50
FGF8	-	-	-	-	51
FGFR1	-	-	-	-	52
MIR1825	-	-	-	-	45
MIR484	-	-	-	-	45
MIR498	-	-	-	-	53
MYCN	-	-	-	-	46
PCA3	-	-	-	-	3
PCGEM	-	-	-	-	3
PRNCR1	-	-	-	-	54
PTENP1	-	-	-	-	55
SCHLAP1	-	-	-	-	56
SPINK1	-	-	-	-	57
XRCC4	-	-	-	-	58

References.

1. Ren S. et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer //European Journal of Cancer. – 2013. – T. 49. – №. 13. – C. 2949-2959.
2. Linja M. J. et al. Expression of androgen receptor coregulators in prostate cancer //Clinical Cancer Research. – 2004. – T. 10. – №. 3. – C. 1032-1040.
3. Zhang H. et al. Long non-coding RNA: a new player in cancer //J Hematol Oncol. – 2013. – T. 6. – №. 1. – C. 1-7.
4. Fan R. et al. Defective DNA strand break repair after DNA damage in prostate cancer cells implications for genetic instability and prostate cancer progression //Cancer research. – 2004. – T. 64. – №. 23. – C. 8526-8533.
5. Perry A. S. et al. The epigenome as a therapeutic target in prostate cancer //Nature Reviews Urology. – 2010. – T. 7. – №. 12. – C. 668-680.
6. Taylor B. S. et al. Integrative genomic profiling of human prostate cancer //Cancer cell. – 2010. – T. 18. – №. 1. – C. 11-22.
7. Kohli M. et al. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer //Advances in urology. – 2012. – T. 2012.
8. Fraser M. et al. PTEN deletion in prostate cancer cells does not associate with loss of RAD51

- function: implications for radiotherapy and chemotherapy //Clinical Cancer Research. – 2012. – T. 18. – №. 4. – C. 1015-1027.
9. Cuzick J. et al. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer //British journal of cancer. – 2013. – T. 108. – №. 12. – C. 2582-258.
 10. Hellowell G. O. et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease //Cancer research. – 2002. – T. 62. – №. 10. – C. 2942-2950.
 11. Roychowdhury S., Chinnaiyan A. M. Advancing precision medicine for prostate cancer through genomics //Journal of Clinical Oncology. – 2013. – T. 31. – №. 15. – C. 1866-1873.
 12. Roychowdhury S., Chinnaiyan A. M. Advancing precision medicine for prostate cancer through genomics //Journal of Clinical Oncology. – 2013. – T. 31. – №. 15. – C. 1866-1873.
 13. Mukherji D., Eichholz A., De Bono J. S. Management of Metastatic Castration-Resistant Prostate Cancer //Drugs. – 2012. – T. 72. – №. 8. – C. 1011-1028.
 14. Clarke R. A. et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression //PloS one. – 2009. – T. 4. – №. 3. – C. e4995.
 15. Beltran H. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity //European urology. – 2013. – T. 63. – №. 5. – C. 920-926.
 16. Phé V., Cussenot O., Rouprêt M. Methylated genes as potential biomarkers in prostate cancer //BJU international. – 2010. – T. 105. – №. 10. – C. 1364-1370.
 17. Beltran H., Rubin M. A. New strategies in prostate cancer: translating genomics into the clinic //Clinical cancer research. – 2013. – T. 19. – №. 3. – C. 517-523.
 18. Ferreira L. B. et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling //BMC cancer. – 2012. – T. 12. – №. 1. – C. 507.
 19. Sarker D. et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer //Clinical Cancer Research. – 2009. – T. 15. – №. 15. – C. 4799-4805.
 20. Ludwig J. A., Weinstein J. N. Biomarkers in cancer staging, prognosis and treatment selection //Nature Reviews Cancer. – 2005. – T. 5. – №. 11. – C. 845-856.
 21. Sardana G. et al. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers //Journal of proteome research. – 2008. – T. 7. – №. 8. – C. 3329-3338.
 22. Ayala G. et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence //Clinical Cancer Research. – 2004. – T. 10. – №. 19. – C. 6572-6578.
 23. Rogers C. G. et al. Prostate cancer detection on urinalysis for α methylacyl coenzyme a racemase protein //The Journal of urology. – 2004. – T. 172. – №. 4. – C. 1501-1503.
 24. Taplin M. E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer //New England Journal of Medicine. – 1995. – T. 332. – №. 21. – C. 1393-1398.
 25. van Leenders G. J. L. H. et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features //European urology. – 2007. – T. 52. – №. 2. – C. 455-463.
 26. Beltran H. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity //European urology. – 2013. – T. 63. – №. 5. – C. 920-926.
 27. Fraser M. et al. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer //Urologic Oncology: Seminars and Original Investigations. – Elsevier, 2015. – T. 33. – №. 2. – C. 85-94.

28. Whitaker H. C. et al. Alterations in β -catenin expression and localization in prostate cancer //The Prostate. – 2008. – T. 68. – №. 11. – C. 1196-1205.
29. Wadelius M. et al. Prostate cancer associated with CYP17 genotype //Pharmacogenetics and Genomics. – 1999. – T. 9. – №. 5. – C. 635-640.
30. Di Lorenzo G. et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer //Clinical Cancer Research. – 2002. – T. 8. – №. 11. – C. 3438-3444.
31. Hümmerich J. et al. Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance: A pilot study in prostate cancer patients receiving radiotherapy //International journal of radiation biology. – 2006. – T. 82. – №. 8. – C. 593-604.
32. Wang Q. et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer //Cell. – 2009. – T. 138. – №. 2. – C. 245-256.
33. Cairns P. et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation //Clinical Cancer Research. – 2001. – T. 7. – №. 9. – C. 2727-2730.
34. Ren S. et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer //European Journal of Cancer. – 2013. – T. 49. – №. 13. – C. 2949-2959.
35. Yang G. et al. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression //Cancer. – 2005. – T. 103. – №. 6. – C. 1186-1194.
36. Karantanos T., Corn P. G., Thompson T. C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches //Oncogene. – 2013. – T. 32. – №. 49. – C. 5501-5511.
37. Pflueger D. et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer //Neoplasia. – 2009. – T. 11. – №. 8. – C. 804-W18.
38. Bowen C. et al. Loss of NKX3. 1 expression in human prostate cancers correlates with tumor progression1, 2 //Cancer research. – 2000. – T. 60. – №. 21. – C. 6111-6115.
39. Xu L. L. et al. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate //Genomics. – 2000. – T. 66. – №. 3. – C. 257-263.
40. Kleer C. G. et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast //Breast cancer research and treatment. – 2005. – T. 93. – №. 2. – C. 101-110.
41. Tatarov O. et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer //Clinical Cancer Research. – 2009. – T. 15. – №. 10. – C. 3540-3549.
42. Laxman B. et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer //Cancer research. – 2008. – T. 68. – №. 3. – C. 645-649.
43. Mahajan K., Mahajan N. P. ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers //Oncogene. – 2014.
44. Bauer J. J. et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer //The Journal of urology. – 1996. – T. 156. – №. 4. – C. 1511-1516.
45. Haj-Ahmad T. A., Abdalla M. A. K., Haj-Ahmad Y. Potential urinary protein biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients //Journal of Cancer. – 2014. – T. 5. – №. 2. – C. 103.
46. Mosquera J. M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer //Neoplasia. – 2013. – T. 15. – №. 1. – C. 1-IN4.
47. Dai J. et al. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms //Cancer research. – 2008. – T. 68. – №. 14. – C. 5785-5794.

48. Xiao D. et al. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis //Carcinogenesis. – 2003. – T. 24. – №. 5. – C. 891-897.
49. Sivaprasad U., Abbas T., Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells //Molecular cancer therapeutics. – 2006. – T. 5. – №. 9. – C. 2310-2316.
50. Agalliu I. et al. Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study //Cancer Causes & Control. – 2010. – T. 21. – №. 2. – C. 289-300.
51. Rajan P. et al. Alternative splicing and biological heterogeneity in prostate cancer //Nature Reviews Urology. – 2009. – T. 6. – №. 8. – C. 454-460.
52. Giri D., Ropiquet F., Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer //Clinical Cancer Research. – 1999. – T. 5. – №. 5. – C. 1063-1071.
53. Shi X. B. et al. MicroRNAs and prostate cancer //Journal of cellular and molecular medicine. – 2008. – T. 12. – №. 5a. – C. 1456-1465.
54. Chung S. et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility //Cancer science. – 2011. – T. 102. – №. 1. – C. 245-252.
55. Martens-Uzunova E. S. et al. Long noncoding RNA in prostate, bladder, and kidney cancer //European urology. – 2014. – T. 65. – №. 6. – C. 1140-1151.
56. Prensner J. R. et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex //Nature genetics. – 2013. – T. 45. – №. 11. – C. 1392-1398.
57. Laxman B. et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer //Cancer research. – 2008. – T. 68. – №. 3. – C. 645-649.
58. Fan R. et al. Defective DNA strand break repair after DNA damage in prostate cancer cells implications for genetic instability and prostate cancer progression //Cancer research. – 2004. – T. 64. – №. 23. – C. 8526-8533.